Showing results (1211-1220 of 3,716) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|July 1, 1989
Elliptinium: phase II study in advanced measurable breast cancerJ Treat, A Greenspan, A Rahman, et al.Investigational New Drugs|July 1, 1989
Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trialB Dana, S Dahlberg, B Schnitzer, et al.Investigational New Drugs|July 1, 1989
Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastineR H Earhart, J D Khandekar, D Faraggi, et al.Investigational New Drugs|October 1, 2016
Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experienceManojkumar Bupathi, Joud Hajjar, Stacie Bean, et al.Investigational New Drugs|February 3, 2017
First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumorsS Fu, H Hirte, S Welch, et al.Investigational New Drugs|January 24, 2017
Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancerL van Andel, S Fudio, H Rosing, et al.Investigational New Drugs|August 2, 2003
Use of positron emission tomography in anticancer drug developmentEric O Aboagye, Patricia M PriceInvestigational New Drugs|August 2, 2003
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experienceKaren S Blesch, Ronald Gieschke, Yuko Tsukamoto, et al.Investigational New Drugs|July 1, 1992
Phase II clinical study of pirarubicin in hormone resistant prostate cancerB L Rapoport, G FalksonInvestigational New Drugs|January 24, 2004
Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibitionJubilee R Stewart, Catherine A O'BrianPageof 372